What’s the big hur­ry, No­var­tis? Phar­ma gi­ant scores a PRV short­cut for $130M

No­var­tis $NVS is mov­ing up the lad­der of Big Phar­ma com­pa­nies with the most ag­gres­sive de­vel­op­ment groups in the in­dus­try. To­day we learned that the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.